<i>APOE</i> ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals

Blood phosphorylated tau (p-tau)217 increases faster in apolipoprotein E (APOE) ɛ4 carriers with amyloid pathology. p-tau181 and p-tau231 do not increase faster in APOE ɛ4 carriers. APOE ɛ4 carriership does not change p-tau in individuals without amyloid pathology.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz.71048
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals

Tharick Ali Pascoal, Nesrine Rahmouni, Marcel S. Woo, Gassan Massarweh et al.
Alzheimer s & Dementia
Alzheimer's disease research and treatments
article

APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals

Tharick Ali Pascoal, Nesrine Rahmouni, Marcel S. Woo, Gassan Massarweh, Jaime Fernandez‐Arias, Arthur C. Macedo, Tevy Chan, Firoza Zubeida Lussier, Robert Hopewell, Kaj Blennow, Yansheng Zheng, Yi‐Ting Wang, Cécile Tissot, Serge Gauthier, Jenna Stevenson, Lydia Trudel, Stuart William Mitchell, Jean‐Paul Soucy, Joseph Therriault, Kely Quispialaya‐Socualaya, Stijn Servaes, Seyyed Ali Hosseini, Marina Goncalves, Étienne Aumont, Pedro Rosa‐Neto, Gleb Bezgin, Brandon Hall, Henrik Zetterberg, Paolo Vitali, Andréa L. Benedet
article en

Abstract

Blood phosphorylated tau (p-tau)217 increases faster in apolipoprotein E (APOE) ɛ4 carriers with amyloid pathology. p-tau181 and p-tau231 do not increase faster in APOE ɛ4 carriers. APOE ɛ4 carriership does not change p-tau in individuals without amyloid pathology.

Alzheimer s & DementiaVol. 21(12)
Montreal Neurological Institute and Hospital (CA), Allen Institute for Brain Science (US), Lawrence Berkeley National Laboratory (US), Universität Hamburg (DE), University of Pittsburgh (US), Sahlgrenska University Hospital (SE), Alzheimer’s Disease Neuroimaging Initiative (US), University Medical Center Hamburg-Eppendorf (DE), UK Dementia Research Institute (GB), Institute of Neuroimmunology of the Slovak Academy of Sciences (SK), University College London (GB), McGill University (CA), University of Gothenburg (SE)
Openalex Percentile: Top 33%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.